BJMO - 2021, issue SPECIAL, march 2021
N. Sundahl MD, PhD, N. MartĂnez Chanzá MD, prof. J. Catto
During the 2021 Belgian Multidisciplinary meeting on Urological Cancers (BMUC) three presentations were given on the subject of bladder preservation in muscle invasive bladder cancer (MIBC). The first presentation by Dr. Nora Sundahl, from the department of radiation oncology, University of Gent, Belgium, addressed the question whether it is best to use radio-chemotherapy, radio-immunotherapy or a combination of all three in patients with muscle invasive bladder cancer (MIBC). Dr. Nieves Martinez-Chanza, from the Medical Oncology department at Jules Bordet Institute, Brussels, Belgium, aimed to answer the question whether neo-adjuvant immunotherapy is already good enough as a treatment option. Lastly Prof. James Catto, professor in Urological Surgery at the University of Sheffield and Urological Surgeon at Sheffield Teaching Hospital discussed four common clinical assumptions around radical cystectomy (RC) and the role of RC in current practice. Although there is some overlap in the discussed topics we will honour the presenters interpretations of the subject by discussing them separately.
Read moreBJMO - 2021, issue SPECIAL, march 2021
M. Gizzi MD
In recent years, we have witnessed a number of exciting therapeutic innovations for patients with metastatic urothelial cancer (mUC). During a lecture at the 2021 annual BMUC meeting Dr. Marco Gizzi provided an overview of these advances.
Read moreBJMO - 2021, issue SPECIAL, march 2021
R. Huddart PhD
Testicular germ cell tumours (TGCTs) are the most common cancer in men between the ages of 15 and 40 years. Luckily, the majority of these patients can expect to be cured. However, the optimal follow-up for patients after their initial management is still subject to debate. During a keynote lecture at the 2021 annual BMUC meeting, Prof Robert Huddart discussed some of the key aspects of this follow-up process.
Read moreBJMO - 2021, issue Special, december 2021
J. Blokken PhD, PharmD, T. Feys MBA, MSc
In the field of Human Epidermal Growth Factor Receptor 2 (HER2) positive early breast cancer, an interesting Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY trial was presented at SABCS 2020. In addition, BluePrint RNA sequencing was used in an attempt to predict the benefit of adjuvant pertuzumab in this trial. Other interesting data in early HER2-positive breast cancer came from the use of neratinib as extended adjuvant therapy. In the metastatic setting, results of the PERTAIN study, the first randomised phase II trial to assess the addition of pertuzumab to trastuzumab and an aromatase inhibitor in the presence or absence of induction chemotherapy, were presented. Finally, a long list of abstracts featured results with novel HER2-directed therapies, including the antibody-drug conjugate trastuzumab deruxtecan, the tyrosine kinase inhibitor tucatinib and the investigational monoclonal antibody margetuximab.
Read moreBJMO - 2021, issue Special, december 2021
T. Feys MBA, MSc, T. Rawson MSc
Among patients with early breast cancer (BC), approximately 75% present with a luminal tumour (HR+).1 In addition to being the most common BC subtype, luminal BC also causes most deaths.2 Interestingly, the deaths caused by this BC subtype occur over a longer period of time compared to what is seen with HER2-positive and triple negative breast cancer (TNBC).3,4 As such, it is safe to say that luminal BC continues to be an unmet clinical need. To address this need, a long list of clinical trials are looking into novel strategies to optimize the management of patents with luminal BC. SABCS 2020 featured a plethora of abstracts discussing updates of pivotal trials in luminal breast cancer in addition to studies generating promising results with novel therapeutic agents in patients with more advanced HR+ BC.
Read moreBJMO - 2021, issue Special, december 2021
J. Blokken PhD, PharmD, T. Feys MBA, MSc
Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer that is prone to early recurrence. In recent years, however, promising data were generated with immunotherapy-based treatment regimens in both the neoadjuvant and metastatic setting. Several updates of these studies were presented at SABCS 2020. In addition, the meeting featured several interesting abstracts discussing potential biomarkers that would facilitate a better treatment selection. In addition to immunotherapy, several novel therapeutics, including antibody-drug conjugates and targeted therapies are emerging in the treatment for patients with metastatic TNBC.
Read moreBJMO - 2021, issue Special, december 2021
J. Blokken PhD, PharmD, T. Feys MBA, MSc
SABCS 2020 featured several interesting presentations in the field of radiotherapy. The PRIME 2 study investigated the impact of omitting postoperative whole breast radiotherapy in older, low-risk women with early invasive breast cancer. Outcomes of the phase III BIG 3-07/TROG 07.01 trial were also reported providing improved insights into the optimal radiation dose and fractionation schedule for non-low risk ductal carcinoma in situ of the breast. Other interesting topics included the comparison of patient and physician reports of toxicity after breast radiotherapy and the finding that radiation therapy improves survival in early-stage HER2-positive breast cancer with a high-levels of tumour infiltrating lymphocytes. Finally, we report on the results of a retrospective analysis assessing the feasibility of radiation therapy de-escalation in patients with stage I, node-negative, HER2-positive breast cancer.
Read more
Top
